SCHEMBL30353142

SCHEMBL30353142

CCOc1cnc(N(CC)CC)nc1Nc1cc(C)[nH]n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
HSD17B10 Q99714 1/20 0.42
IGF1R P08069 8/20 0.40
FGFR1 P11362 6/20 0.40
KDR P35968 6/20 0.40
INSR P06213 2/20 0.40
AURKA O14965 2/20 0.40
SRC P12931 2/20 0.40
GSK3B P49841 2/20 0.40
PLK4 O00444 3/20 0.39
PAK4 O96013 2/20 0.39
GRM5 P41594 3/20 0.39
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
MPI P34949 1/20 0.37
JAK2 O60674 2/20 0.36
JAK3 P52333 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30353151 0.80 MEN1 (0.43) MEN1HTTKMT2AHSD17B10IGF1R
SCHEMBL30353140 0.72 MEN1 (0.40) MEN1HTTKMT2AHSD17B10IGF1R
SCHEMBL30353156 0.69 MEN1 (0.44) MEN1HTTKMT2AHSD17B10IGF1R
SCHEMBL18154671 0.69 MEN1 (0.47) MEN1HTTKMT2AHSD17B10IGF1R
SCHEMBL14771711 0.69 PLK4 (0.55) MEN1HTTKMT2AHSD17B10IGF1R
SCHEMBL30353148 0.69 MEN1 (0.47) MEN1HTTKMT2AHSD17B10IGF1R
SCHEMBL16356862 0.68 AURKA (0.50) IGF1RFGFR1KDRAURKASRC
SCHEMBL30353129 0.68 MEN1 (0.40) MEN1HTTKMT2AHSD17B10IGF1R
SCHEMBL802014 0.67 AURKA (0.65) AURKASRCGSK3BJAK2JAK3
SCHEMBL14771762 0.67 AURKA (0.51) MEN1HTTKMT2AHSD17B10IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11612604-B2 Methods of treating cancer with PLK4 inhibitors LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) 2023-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11612604-B2 Methods of treating cancer with PLK4 inhibitors PLK4, PLK2, PLK3 MEN1 3546/4885HTT 3372/4885KMT2A 1059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.